Loading...
Standard first-line chemotherapy for advanced cholangiocarcinoma is gemcitabine and cisplatin. Recent data support the use of FOLFOX as a second-line regimen, but the benefits are marginal. Given the regulatory approval of specific molecular targeted agents in later-line therapy, genomic profiling of these cancers is now mandatory.
Investigators in South Korea report results of an industry-sponsored, open-label, randomized phase 2 trial comparing treatment with infusional 5-fluorouracil (5-FU) and leucovorin with or without the addition of liposome encapsulated irinotecan in patients with advanced biliary cancer that progressed on gemcitabine and cisplatin. Of 174 patients, half had progression after a median of less than 5.1 months of prior…